New Drugs 2011-2012- Pharmacist

  Price  

  Credits  2

This product is currently out of stock and unavailable.


Format
The FDA was busy approving 35 new drugs during 2011, the second highest number approved in 10 years. This issue provides detailed reviews of the new drugs most likely to be encountered in the outpatient or community practice setting. These include fidaxomicin (DificidTM), an important drug for Clostridium difficile infection; spinosad (NatrobaTM), an improved treatment for head lice; indacaterol (ArcaptaTM, NeohalerTM) and roflumilast (Daliresp®), 2 drugs for COPD; and ticagrelor (BrilintaTM), a new antiplatelet agent. The second warfarin alternative to reach the market, rivaroxaban (Xarelto®), is also reviewed. It is approved for stroke prevention in patients with atrial fibrillation, and deep vein thrombosis (DVT) prevention in patients having hip or knee replacement. New indications are discussed for 3 commonly used drugs: gabapentin enacarbil ER (Horizant®), tadalafil (Cialis®), and zolpidem sublingual (Intermezzo®). Two new drugs for hepatitis C that are major breakthroughs in therapy, boceprevir (VictrelisTM) and telaprevir (IncivekTM), and an important 3-drug combination for HIV infection, rilpirivine (EdurantTM) were covered previously in The Rx Consultant (November, 2011 and February 2012, respectively). Useful tables summarize the key points of the new drugs and products. Throughout the issue practical patient counseling points are highlighted separately for easy access.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 0428-0000-12-004-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.